title: P2X(7) receptors in cerebral ischemia.
abstract: Cerebral ischemia is one of the most common diseases resulting in death and disability in aged people. It leads immediately to rapid energy failure, ATP depletion, and ionic imbalance, which increase extracellular ATP levels and accordingly activate P2X7 receptors. These receptors are ATP-gated cation channels and widely distributed in nerve cells, especially in the immunocompetent cells of the brain. Currently, interest in the roles of P2X7 receptors in ischemic brain injury is growing. In this review, we discuss recent research progress on the actions of P2X7 receptors, their possible mechanisms in cerebral ischemia, and the potential therapeutic value of P2X7 receptor antagonists which may provide a new target both for clinical and for research purposes.
authors: Department of Physiology, Dalian Medical University, Dalian, 116044, China.
authors: Hui-Yu
authors: HY
authors: Bai
authors: Ai-Ping
authors: AP
authors: Li
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D002545:Brain Ischemia / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism; D006801:Humans; D009474:Neurons / Q000378:metabolism / Q000502:physiology; D058486:Receptors, Purinergic P2X7 / Q000378:metabolism*
chemical_list: D058486:Receptors, Purinergic P2X7; D000255:Adenosine Triphosphate; D002118:Calcium
references: J Neurosci. 2003 Feb 15;23(4):1320-8
references: 12598620
references: Prog Neurobiol. 2006 Apr;78(6):327-46
references: 16697102
references: Trends Neurosci. 2009 Jan;32(1):19-29
references: 19008000
references: Nat Rev Neurosci. 2006 Jun;7(6):423-36
references: 16715052
references: Cell Mol Neurobiol. 2010 Jul;30(5):683-92
references: 20099024
references: Purinergic Signal. 2005 Sep;1(3):219-27
references: 18404507
references: Trends Pharmacol Sci. 2010 May;31(5):229-37
references: 20227116
references: J Neurosci. 2011 Sep 7;31(36):12992-3001
references: 21900578
references: FEBS Lett. 2008 Nov 26;582(28):3948-53
references: 18977353
references: Pharmacol Rev. 2001 Mar;53(1):107-18
references: 11171941
references: Exp Brain Res. 2002 Dec;147(3):353-9
references: 12428143
references: J Neurochem. 2011 May;117(4):712-23
references: 21395581
references: Int J Biochem Cell Biol. 2010 Nov;42(11):1753-6
references: 20599520
references: Neurochem Int. 2005 Nov;47(6):442-8
references: 16029911
references: Neuroscience. 2007 Oct 12;149(1):99-111
references: 17850981
references: Nature. 2002 Nov 7;420(6911):42
references: 12422208
references: Acta Pharmacol Sin. 2004 May;25(5):617-22
references: 15132828
references: J Neurochem. 2002 Jun;81(6):1196-211
references: 12068068
references: J Cereb Blood Flow Metab. 2004 Apr;24(4):392-8
references: 15087708
references: Annu Rev Physiol. 2009;71:333-59
references: 18851707
references: J Immunol. 1999 Jul 15;163(2):558-61
references: 10395640
references: J Physiol. 1999 Sep 1;519 Pt 2:335-46
references: 10457053
references: Neurosci Lett. 2008 Nov 28;446(1):45-50
references: 18817842
references: J Pharmacol Exp Ther. 2007 Oct;323(1):70-7
references: 17620457
references: Neurochem Int. 2011 Feb;58(3):376-84
references: 21185900
references: Neurochem Int. 2001 Mar;38(3):189-97
references: 11099776
references: Stroke. 2007 Feb;38(2 Suppl):674-6
references: 17261713
references: J Cereb Blood Flow Metab. 2003 Mar;23(3):381-4
references: 12621313
references: Eur J Neurosci. 2003 Jun;17(11):2267-76
references: 12814360
references: J Neurochem. 2008 Apr;105(1):151-64
references: 18067549
references: J Neuroinflammation. 2012 Jul 12;9:172
references: 22789015
references: J Neuroinflammation. 2012 Apr 18;9:69
references: 22513224
references: J Neurosci. 2007 May 2;27(18):4957-68
references: 17475804
references: J Neurophysiol. 2006 Mar;95(3):1537-44
references: 16354727
references: FASEB J. 2010 Feb;24(2):337-45
references: 19812374
references: Eur J Pharmacol. 2002 Jul 5;447(2-3):261-9
references: 12151017
references: Trends Neurosci. 2006 May;29(5):257-62
references: 16564580
references: J Neurosci. 2004 Jan 7;24(1):1-7
references: 14715932
references: Glia. 2009 Feb;57(3):307-19
references: 18942747
references: Neuroscience. 2005;136(3):615-23
references: 16344139
references: Recent Pat CNS Drug Discov. 2010 Jan;5(1):35-45
references: 19705995
references: Brain Res. 2008 Feb 15;1194:45-55
references: 18177631
references: Neuroscience. 2005;136(3):795-810
references: 16344152
references: CNS Neurol Disord Drug Targets. 2011 Feb;10(1):44-56
references: 21143139
references: J Cereb Blood Flow Metab. 2006 Jul;26(7):974-82
references: 16395292
references: Nat Med. 2004 Aug;10(8):821-7
references: 15258577
references: Physiol Rev. 2002 Oct;82(4):1013-67
references: 12270951
references: Glia. 2006 Aug 15;54(3):234-42
references: 16817206
references: Mol Biol Cell. 2005 Aug;16(8):3659-65
references: 15944221
references: Brain Res. 2008 Feb 21;1195:1-11
references: 18206860
references: Mol Med Rep. 2012 May;5(5):1357-61
references: 22377955
references: J Immunol. 2005 Jun 1;174(11):7268-77
references: 15905573
references: Biol Pharm Bull. 2008 Jun;31(6):1121-30
references: 18520042
references: J Immunol. 2008 Jun 15;180(12):7827-39
references: 18523246
references: Autophagy. 2009 Jul;5(5):723-4
references: 19337025
references: J Neurochem. 2005 Dec;95(5):1421-37
references: 16313518
references: Br J Pharmacol. 2003 Oct;140(3):507-19
references: 14522842
references: Neurobiol Dis. 2012 Mar;45(3):954-61
references: 22186422
references: Anesth Analg. 2007 May;104(5):1136-44, tables of contents
references: 17456664
references: J Neuropathol Exp Neurol. 2004 Jul;63(7):686-99
references: 15290894
references: Arch Immunol Ther Exp (Warsz). 2010 Apr;58(2):91-6
references: 20143170
references: J Neurosci. 2009 Mar 25;29(12):3781-91
references: 19321774
references: Biochim Biophys Acta. 2009 Nov;1787(11):1352-62
references: 19527680
references: Annu Rev Immunol. 2009;27:519-50
references: 19302047
references: J Anat. 2011 Jul;219(1):53-64
references: 21250988